Effect of BRAF-mediated PI3K/Akt/mTOR pathway on biological characteristics and chemosensitivity of NSCLC A549/DDP cells

被引:9
|
作者
Ren, Bingnan [1 ]
Liu, Hongtao [1 ]
Yang, Yupeng [1 ]
Lian, Yufei [1 ]
机构
[1] Hebei Gen Hosp, Dept Pharm, 348 Heping West Rd, Shijiazhuang 050053, Hebei, Peoples R China
关键词
BRAF gene; PI3K; Akt; mTOR signaling pathway; non-small cell lung cancer cells; biological characteristics; chemosensitivity; LUNG-CANCER; ACQUIRED-RESISTANCE; SIGNALING PATHWAY; APOPTOSIS; INVASION; CHEMOTHERAPY; METASTASIS; EXPRESSION; CISPLATIN; GENE;
D O I
10.3892/ol.2021.12845
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The present study aimed to explore the biological characteristics of non-small cell lung cancer (NSCLC) cells and the mechanism of chemosensitivity through the role of the PI3K/Akt/mTOR signaling pathway mediated by BRAF gene silencing. Following cell transfection and grouping, an MTT assay detected the activity of NSCLC cells, a scratch wound test assessed the migration ability, flow cytometry using PI staining detected the cell cycle phase, TUNEL and flow cytometry through Annexin V-PI staining assessed the apoptosis, and colony formation was used to detect the sensitivity of lung cancer cells to cisplatin chemotherapy. Furthermore, the relative expression levels of BRAF, PTEN, PI3K, mTOR mRNA were assessed by RT-qPCR, and the protein expression levels of BRAF, PTEN, PI3K, phosphorylated (p)-PI3K, Akt, p-Akt, mTOR, p-mTOR, cisplatin resistance-related enzymes ERCC1 and BRCA1, apoptotic proteins Bax and Bcl-2 were assessed by western blotting. Compared with the control group and NC group, there were differences in decreased BRAF mRNA expression levels in the small interfering (si)BRAF group and siBRAF + IGF-1 group (both P<0.05). In addition, compared with the control group, the siBRAF, NVP-BEZ235 and siBRAF + NVP-BEZ235 groups had significant decreased cell viability at 2-6 days, decreased migration ability, shortened proportion of S-phase cells, increased proportion of G(1)/G(0)-phase cells, increased apoptosis rate, decreased number of colony-forming cells, decreased mRNA expression of PI3K, Akt and mTOR, increased PTEN mRNA expression, decreased protein expression levels of PI3K, p-PI3K, Akt, p-Akt, mTOR, p-mTOR, ERCC1, BRCA1 and Bcl-2, and increased protein expression levels of PTEN and Bax (all P<0.05); and more obvious trends were revealed in the siBRAF + NVP-BEZ235 group (all P<0.05); whereas opposite results were detected in the siBRAF + IGF-1 group when compared with the siBRAF group and NVP-BEZ235 group (all P<0.05). Silencing of BRAF gene expression to inhibit the activation of the PI3K/Akt/mTOR signaling pathway exerted a synergistic effect decreasing cell viability, inhibiting the cell cycle and migration, increasing the apoptosis rate, decreasing the number of colony-forming cells and increasing chemosensitivity of NSCLC. Activation of the PI3K/Akt/mTOR signaling pathway may reverse the role of silencing of BRAF gene expression, providing a potential approach for improving the chemosensitivity of NSCLC. The present study for the first time, to the best of our knowledge, clarified the possible mechanism of NSCLC cell biological characteristic changes and chemosensitivity from the perspective of BRAF gene silencing and PI3K/Akt/mTOR signaling pathway activation, providing a potential reference for suppressing tumor aggravation and improving the therapeutic outcomes of NSCLC at the genetic level.
引用
收藏
页数:14
相关论文
共 50 条
  • [41] The exosome-mediated PI3k/Akt/mTOR signaling pathway in cervical cancer
    Zhang, Wenyuan
    Zhou, Qing
    Wei, Yunhai
    Da, Miao
    Zhang, Chun
    Zhong, Jing
    Liu, Jin
    Shen, Junjun
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2019, 12 (07): : 2474 - 2484
  • [42] Interferon alpha mediated suppression of JCV is PI3K/AKT and mTOR pathway dependent
    Caocci, Maurizio
    Bellizzi, Anna
    Kassa, Workineh D.
    White, Martyn K.
    Wollebo, Hassen S.
    JOURNAL OF NEUROIMMUNE PHARMACOLOGY, 2018, 13 : S12 - S12
  • [43] The Exosome-Mediated PI3K/Akt/mTOR Signaling Pathway in Neurological Diseases
    Iranpanah, Amin
    Kooshki, Leila
    Moradi, Seyed Zachariah
    Saso, Luciano
    Fakhri, Sajad
    Khan, Haroon
    PHARMACEUTICS, 2023, 15 (03)
  • [44] Targeting the PI3K/Akt/mTOR Pathway in Ocular Neovascularization
    Sasore, Temitope
    Reynolds, Alison L.
    Kennedy, Breandan N.
    RETINAL DEGENERATIVE DISEASES: MECHANISMS AND EXPERIMENTAL THERAPY, 2014, 801 : 805 - 811
  • [45] PI3K/AKT Pathway is inhibited in NSCLC cell line A549 by downregulation of EGFR via an HSP-90 inhibitor Gedunin
    Hasan, A.
    Haque, E.
    Kamil, M.
    Fatima, J.
    Irfan, S.
    Khatoon, A.
    Yusuf, M. Aslam
    Mir, S. S.
    CANCER MEDICINE, 2018, 7 : 25 - 26
  • [46] Inhibition of PI3K/AKT/mTOR pathway for the treatment of endometriosis
    Barra, Fabio
    Desideri, Lorenzo Ferro
    Ferrero, Simone
    BRITISH JOURNAL OF PHARMACOLOGY, 2018, 175 (17) : 3626 - 3627
  • [47] Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors
    LoRusso, Patricia Mucci
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (31) : 3803 - +
  • [48] Status of PI3K/Akt/mTOR Pathway Inhibitors in Lymphoma
    Westin, Jason R.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2014, 14 (05): : 335 - 342
  • [49] Evaluation of the PI3K/AKT/mTOR pathway in multiple sclerosis
    Mammana, Santa
    Fagone, Paolo
    Cavalli, Eugenio
    Basile, Maria Sofia
    Petralia, Maria Cristina
    Nicoletti, Ferdinando
    Mangano, Katia
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2017, 40 : S51 - S51
  • [50] Targeting the PI3K/Akt/mTOR Pathway - Beyond Rapalogs
    Markman, Ben
    Dienstmann, Rodrigo
    Tabernero, Josep
    ONCOTARGET, 2010, 1 (07) : 530 - 543